Liver Disease

Categories: Blood diseases, Bone diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Metabolic diseases, Nephrological diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Liver Disease

MalaCards integrated aliases for Liver Disease:

Name: Liver Disease 12 15 37 17
Liver Diseases 54 42 44 70
Liver Failure 29 54 6 70
Abnormality of the Liver 29 6
Liver Dysfunction 54 70
Disorder of Liver 12
Hepatic Disorder 12
Hepatic Disease 15


External Ids:

Disease Ontology 12 DOID:409
ICD9CM 34 573.9
MeSH 44 D008107
NCIt 50 C3196
SNOMED-CT 67 62857009
UMLS 70 C0023895 C0085605 C0086565

Summaries for Liver Disease

MedlinePlus : 42 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. There are many kinds of liver diseases: Diseases caused by viruses, such as hepatitis A, hepatitis B, and hepatitis C Diseases caused by drugs, poisons, or too much alcohol. Examples include fatty liver disease and cirrhosis. Liver cancer Inherited diseases, such as hemochromatosis and Wilson disease Symptoms of liver disease can vary, but they often include swelling of the abdomen and legs, bruising easily, changes in the color of your stool and urine, and jaundice, or yellowing of the skin and eyes. Sometimes there are no symptoms. Tests such as imaging tests and liver function tests can check for liver damage and help to diagnose liver diseases.

MalaCards based summary : Liver Disease, also known as liver diseases, is related to fatty liver disease and non-alcoholic fatty liver disease, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Liver Disease is MEG3 (Maternally Expressed 3), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers and FOXA2 and FOXA3 transcription factor networks. The drugs Telmisartan and Amlodipine have been mentioned in the context of this disorder. Affiliated tissues include liver, bone marrow and endothelial, and related phenotypes are homeostasis/metabolism and cellular

Wikipedia : 73 Liver disease (also called hepatic disease) is a type of damage to or disease of the liver. Whenever the... more...

Related Diseases for Liver Disease

Diseases in the Liver Disease family:

Liver Failure, Infantile, Transient Infantile Liver Failure Syndrome 1
Infantile Liver Failure Syndrome 2 Infantile Liver Failure Syndrome 3
Infantile Liver Failure Syndrome Acute Liver Failure

Diseases related to Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1903)
# Related Disease Score Top Affiliating Genes
1 fatty liver disease 33.9 SLC17A5 PNPLA3 GPT GGT1 ADIPOQ
2 non-alcoholic fatty liver disease 33.8 SERPINA1 PNPLA3 GPT GGT1 ALB ADIPOQ
3 polycystic liver disease 33.6 SERPINA1 SEC63 PRKCSH PKHD1 PKD1 GGT1
4 polycystic liver disease 1 with or without kidney cysts 33.3 SEC63 PRKCSH PKHD1 PKD1
5 non-alcoholic steatohepatitis 33.1 PNPLA3 HGF GPT ALB ADIPOQ
6 polycystic kidney disease 4 with or without polycystic liver disease 33.1 SEC63 PRKCSH PKHD1 PKD1 GANAB
7 alcoholic hepatitis 32.9 SLC17A5 PNPLA3 HGF GPT GGT1 F2
8 polycystic kidney disease 1 with or without polycystic liver disease 32.9 SEC63 PRKCSH PKHD1 PKD1 GANAB
9 polycystic kidney disease 2 with or without polycystic liver disease 32.9 SEC63 PRKCSH PKHD1 PKD1
10 alpha-1-antitrypsin deficiency 32.8 SERPINA1 GPT F2 ALB AFP
11 primary biliary cholangitis 32.8 SLC17A5 GPT GGT1 F2 DLAT ALB
12 hepatic vascular disease 32.7 SERPINA1 PKHD1 GPT F2 ALB AFP
13 alcohol use disorder 32.7 SLC17A5 GPT GGT1 ALB
14 wilson disease 32.7 SLC17A5 PNPLA3 GPT
15 cholangitis, primary sclerosing 32.6 SERPINA1 GPT GGT1 F2 DLAT ALB
16 hepatic encephalopathy 32.6 SLC17A5 GPT F2 ALB
17 sclerosing cholangitis 32.5 GPT GGT1 F2 ALB ABCB11
18 hemochromatosis, type 1 32.5 SERPINA1 GPT ALB AFP
19 portal hypertension 32.4 PNPLA3 PKHD1 GPT F2 ALB
20 hepatorenal syndrome 32.4 GPT F2 ALB
21 cholestasis 32.4 SLC17A5 SERPINA1 HSD3B7 GPT GGT1 F2
22 acute liver failure 32.4 SLC17A5 HGF GPT F2
23 viral hepatitis 32.3 SLC17A5 SERPINA1 PNPLA3 GPT GGT1 F2
24 alcoholic liver cirrhosis 32.3 SLC17A5 PNPLA3 HGF GPT F2 ALB
25 cholangitis 32.3 GPT GGT1 F2 DLAT ALB ABCB11
26 hepatitis 32.2 SLC17A5 GPT GGT1 F2 AFP
27 autoimmune hepatitis 32.2 SLC17A5 GPT GGT1 F2 DLAT ALB
28 tyrosinemia, type i 32.2 SERPINA1 FAH AFP
29 congenital hepatic fibrosis 32.2 PKHD1 PKD1
30 hepatic coma 32.2 GPT F2 ALB AFP
31 hepatitis b 32.1 SLC17A5 GPT GGT1 F2 ALB AFP
32 liver cirrhosis 32.0 SLC17A5 SERPINA1 PNPLA3 MEG3 HGF GPT
33 type 2 diabetes mellitus 32.0 SLC17A5 PNPLA3 HGF GPT GGT1 F2
34 polycystic kidney disease 31.9 PRKCSH PKHD1 PKD1 GANAB ALB
35 hepatitis a 31.9 SERPINA1 GPT F2 ALB AFP
36 esophageal varix 31.9 SERPINA1 PKHD1 GPT F2 ALB AFP
37 autosomal dominant polycystic kidney disease 31.8 SEC63 PRKCSH PKHD1 PKD1 GANAB ALB
38 biliary atresia 31.7 HGF GPT GGT1 F2 ALB ABCB11
39 kidney disease 31.7 PKHD1 PKD1 HGF GANAB ALB ADIPOQ
40 sleep apnea 31.7 GPT ALB ADIPOQ
41 hyperuricemia 31.6 GPT GGT1 ALB
42 hepatitis e 31.6 GPT F2 ALB
43 schistosomiasis 31.5 GPT F2 ALB
44 bilirubin metabolic disorder 31.5 SLC17A5 SERPINA1 HSD3B7 GPT GGT1 FAH
45 obstructive jaundice 31.4 SLC17A5 HGF GPT GGT1 F2 ALB
46 hypersplenism 31.4 GPT F2 ALB
47 budd-chiari syndrome 31.3 F2 ALB AFP
48 cholecystitis 31.3 GPT F2 ALB
49 extrahepatic cholestasis 31.3 GPT GGT1 ABCB11
50 inherited metabolic disorder 31.2 SERPINA1 PNPLA3 GPT F2 ALB ADIPOQ

Comorbidity relations with Liver Disease via Phenotypic Disease Network (PDN):

Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hepatic Encephalopathy Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Liver Disease:

Diseases related to Liver Disease

Symptoms & Phenotypes for Liver Disease

UMLS symptoms related to Liver Disease:

nausea and vomiting; constipation; abdominal pain; diarrhea; hepatosplenomegaly; dyspepsia; icterus; heartburn; gastrointestinal gas; digestive system symptom; liver tender; abnormal bruising

MGI Mouse Phenotypes related to Liver Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.07 ABCB11 ADIPOQ AFP ALB F2 FAH
2 cellular MP:0005384 10.06 ADIPOQ ALB F2 FAH GGT1 HGF
3 liver/biliary system MP:0005370 9.93 ABCB11 ADIPOQ AFP ALB FAH HGF
4 mortality/aging MP:0010768 9.86 ABCB11 ADIPOQ AFP ALB DLAT F2
5 renal/urinary system MP:0005367 9.23 ADIPOQ ALB FAH GGT1 PKD1 PKHD1

Drugs & Therapeutics for Liver Disease

Drugs for Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 746)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
Amlodipine Approved Phase 4 88150-42-9 2162
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
Glimepiride Approved Phase 4 93479-97-1 3476
Temocillin Approved, Investigational Phase 4 66148-78-5
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
Simeprevir Approved Phase 4 923604-59-5 66576988
Citalopram Approved Phase 4 59729-33-8 2771
Promethazine Approved, Investigational Phase 4 60-87-7 4927
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
Methocarbamol Approved, Vet_approved Phase 4 532-03-6 4107
Pantoprazole Approved Phase 4 102625-70-7 4679
Ibuprofen Approved Phase 4 15687-27-1 3672
Remifentanil Approved Phase 4 132875-61-7 60815
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
Glucagon Approved Phase 4 16941-32-5
Ezetimibe Approved Phase 4 163222-33-1 150311
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
Desflurane Approved Phase 4 57041-67-5 42113
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
Liraglutide Approved Phase 4 204656-20-2 44147092
Gliclazide Approved Phase 4 21187-98-4 3475
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
Ethanolamine oleate Approved Phase 4 2272-11-9
Ethiodized oil Approved, Investigational Phase 4 8008-53-5
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
Insulin aspart Approved Phase 4 116094-23-6 16132418
Insulin detemir Approved Phase 4 169148-63-4 5311023
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
Pravastatin Approved Phase 4 81093-37-0 54687
Haloperidol Approved Phase 4 52-86-8 3559
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 644073 40400
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
Nevirapine Approved Phase 4 129618-40-2 4463
Phentermine Approved, Illicit Phase 4 122-09-8 4771
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
Methadone Approved Phase 4 76-99-3 4095
Deferiprone Approved Phase 4 30652-11-0 2972
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
Lactulose Approved Phase 4 4618-18-2 11333
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
Midazolam Approved, Illicit Phase 4 59467-70-8 4192

Interventional clinical trials:

(show top 50) (show all 2245)
# Name Status NCT ID Phase Drugs
1 Granulocyte Colony-stimulating Factor(G-CSF) in the Treatment of Hepatic Failure: a Prospective Randomized Controlled Clinical Study Unknown status NCT02331745 Phase 4 Granulocyte colony-stimulating factor;standard treatment
2 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Unknown status NCT02757170 Phase 4
3 Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis Unknown status NCT02335632 Phase 4 Probiotics (Lacidofil®);Placebo
4 The Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4 UDCA;Sitagliptin
5 Influence of CYP3A5 Polymorphism on Liver Function Abnormality and the Trough Level Change After Conversion From Tacrolimus (Bid) to Advagraf® (qd) in Stable Liver Transplant Recipients Unknown status NCT02882113 Phase 4 Advagraf
6 Randomised Controlled Study Comparing Use of Popofol Plus Fentanyl Versus Midazolam Plus Fentanyl as Sedation in Diagnostic Endoscopy in Patients With Advanced Liver Disease. Unknown status NCT03063866 Phase 4 Propofol;Midazolam;Fentanyl
7 The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme, a Randomised Controlled Trial Unknown status NCT01429779 Phase 4 Movicol
8 Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography Unknown status NCT00155376 Phase 4 morphine and glucagon
9 THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01956825 Phase 4
10 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
11 Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
12 Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Unknown status NCT02649465 Phase 4 Tofogliflozin;Glimepiride
13 Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease (BRAVE): Korean Nation-wide Multicenter Retrospective and Prospective Observational Cohort Study Unknown status NCT02837302 Phase 4 Livact
14 A Randomized, Open Label, Phase IV, Multicenter Study for Efficacy and Safety of Lamivudine Versus Entecarvir Therapy in HBV-related Advanced Liver Disease Patients With High Viral Load and Normal or Slightly Elevated Transaminase Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
15 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
16 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Fatty Liver Disease Prediabetic Mexican Patients Unknown status NCT02051842 Phase 4 Metadoxine
17 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
18 Pilot Study to Assess the Antiviral Activity and Safety of Besifovir Dipivoxil 150mg and L-carnitine 660mg Compared to Tenofovir Alafenamide 25mg in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Unknown status NCT03604016 Phase 4 Besifovir dipivoxil;L-carnitine;Tenofovir Alafenamide
19 Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods Unknown status NCT02210715 Phase 4 Isentress.
20 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
21 Temocillin Pharmacokinetics in Paediatrics Unknown status NCT02260102 Phase 4 Temocillin
22 The Safety and Immunogenicity of 10μg/0.5ml Recombinant Hepatitis B Vaccines(Saccharomyces Cerevisiae) in the Healthy Neonates Unknown status NCT02764671 Phase 4
23 A Study Comparing Thymoglobulin to Tacrolimus in Liver Transplant and Impact on Renal Function Unknown status NCT00564538 Phase 4 anti-thymocyte globulin (rabbit);tacrolimus
24 A Pharmacokinetic and Pharmacodynamic Study of Glufast Tablets 10 mg (Mitiglinide) in Type 2 Diabetes Mellitus Patients With Normal or Moderate Impaired Hepatic Function Completed NCT04349696 Phase 4 Mitiglinide
25 A Single-arm Evaluation of the Safety of Paliperidone Extended-Release (ER) in Subjects With Schizophrenia or Schizoaffective Disorder With Hepatic Disease Completed NCT00535145 Phase 4 Treatment as usual (TAU), Paliperidone ER
26 A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus Completed NCT01327547 Phase 4 Maraviroc;Placebo
27 Tenofovir Reduces Morbidity and Mortality in Patients With Spontaneous Reactivation of Hepatitis B Presenting as Acute-on-chronic Liver Failure (ACLF): A Randomized Placebo Controlled Trial Completed NCT01074645 Phase 4 Tenofovir disoproxil fumarate (TDF)
28 Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients With Graves' Orbitopathy Completed NCT03667157 Phase 4 every week IVMP therapy;very high doses IVMP therapy
29 Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease Completed NCT02366845 Phase 4
30 Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs Completed NCT03133065 Phase 4 treatment of HCV with oral direct acting antiviral therapy
31 Feasibility Study to Prevent Post-ICU Depression Completed NCT00872027 Phase 4 Escitalopram;Placebo
32 Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients Completed NCT02432456 Phase 4 Ketamine;Placebo;Acetaminophen;Ibuprofen;Pantoprazole;Methocarbamol;Opioid
33 Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease Completed NCT01501162 Phase 4 hepatitis, alcohol, probiotics;alcohol, hepatitis, Placebo
34 Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension Completed NCT02489045 Phase 4 SHAPE measurement (Sonazoid ultrasoud contrast agent)
35 Prevention for Surgical Site Infection After Hepatic Resection Completed NCT00659698 Phase 4
36 Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Completed NCT01968395 Phase 4 Caspofungin 70 mg
37 CellCept (Mycophenolate Mofetil, MMF) Maintenance Immunosuppression in Liver Transplant Recipients With Long-term Follow-up Post-transplantation for Non-Autoimmune Liver Disease - A Prospective, Randomized, Multicenter Trial. Completed NCT00206076 Phase 4 mycophenolate mofetil;mycophenolate mofetil
38 An Open-Label, Randomized, Prospective Multicenter Study To Compare The Efficacy And Safety Among 3 Immunosuppressant Treatment Regimens In Patients Receiving A Liver Transplant For ESLD Caused By Chronic Hepatitis C Completed NCT00163657 Phase 4 Daclizumub;Tacrolimus;Cyclosporine;MMF
39 Comparison of Quantiferon-TB Gold Assay With Tuberculin Skin Testing for Detecting Latent Mycobacterium Tuberculosis Infection in Patients With Chronic Liver Disease Awaiting Liver Transplantation Completed NCT00402402 Phase 4
40 A Comparison of Propofol Based Total Intravenous Anesthesia and Desflurane Based Balanced Anesthesia on Hepatic Protection During Living-donor Liver Transplantation Completed NCT02504138 Phase 4 Desflurane balanced anesthesia;Propofol total intravenous anesthesia
41 A Double-Blind, Randomized, Multicenter Trial Examining the Efficacy of Biphenyl Dimethyl Dicarboxylate Combined With Garlic Oil in Patients With Transaminase Elevated Chronic Liver Disease Completed NCT02347319 Phase 4 Pennel;Legalon;Placebo
42 Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
43 PXR-aktivaation Vaikutus Maksan Rasvoittumiseen Completed NCT02329405 Phase 4 Rifampicin;Placebo
44 Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD) Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
45 Sugammadex Versus Neostigmine for Antagonism of Rocuronium-induced Neuromuscular Blockade in Patients With Liver Cirrhosis Undergoing Liver Resection: A Controlled Randomized Study Completed NCT02414880 Phase 4 Sugammadex;Neostigmine;Rocuronium
46 Endoscopic Treatment of Esophageal Varices in Advanced Liver Disease Patients: a Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection Completed NCT00799851 Phase 4 cyanoacrylate injection
47 Prospective Detection of Liver Fibrosis With MRI Compared to Fibroscan and Blood Tests Completed NCT01600105 Phase 4 Perfusion MRI
48 The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease Completed NCT00760513 Phase 4 OMACOR;Placebo oral capsule
49 A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease Completed NCT03434613 Phase 4 Rosuvastatin;Rosuvastatin/ezetimibe combination
50 Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography Completed NCT04038853 Phase 4 1,25-Dihydroxyvitamin D;Placebo

Search NIH Clinical Center for Liver Disease

Inferred drug relations via UMLS 70 / NDF-RT 51 :

Medium chain triglycerides

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Liver Disease cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: liver diseases

Genetic Tests for Liver Disease

Genetic tests related to Liver Disease:

# Genetic test Affiliating Genes
1 Liver Failure 29
2 Abnormality of the Liver 29

Anatomical Context for Liver Disease

MalaCards organs/tissues related to Liver Disease:

Liver, Bone Marrow, Endothelial, Spleen, Bone, T Cells, Ovary

Publications for Liver Disease

Articles related to Liver Disease:

(show top 50) (show all 49943)
# Title Authors PMID Year
Progressive liver injury and increased mortality risk in COVID-19 patients: A retrospective cohort study in China. 42
33727773 2021
Gastroenterological and hepatic manifestations of patients with COVID-19, prevalence, mortality by country, and intensive care admission rate: systematic review and meta-analysis. 42
33664052 2021
Hepatic actinomycosis: a very rare form of actinomycosis. 42
33681913 2021
Elevated hydroxyacylcarnitines in a carrier of LCHAD deficiency during acute liver disease of pregnancy - a common feature of the pregnancy complication? 54 61
20363656 2010
Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. 54 61
20371660 2010
Nonalcoholic fatty liver disease and HFE gene mutations: a Polish study. 61 54
20503453 2010
Beneficial effects of exercise training (treadmill) on insulin resistance and nonalcoholic fatty liver disease in high-fat fed C57BL/6 mice. 54 61
20490434 2010
The PXR is a drug target for chronic inflammatory liver disease. 61 54
20416375 2010
The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. 61 54
20415685 2010
Negative correlation between neuropeptide Y/agouti-related protein concentration and adiponectinemia in nonalcoholic fatty liver disease obese adolescents submitted to a long-term interdisciplinary therapy. 54 61
19942238 2010
Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases. 61 54
20200515 2010
Is alanine aminotransferase level a surrogate biomarker of hepatic apoptosis in nonalcoholic fatty liver disease? 54 61
20406065 2010
Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. 54 61
19881359 2010
Effect of Xuezhikang Capsule on serum tumor necrosis factor-alpha and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia. 54 61
20473736 2010
Hepatic senescence marker protein-30 is involved in the progression of nonalcoholic fatty liver disease. 61 54
19946731 2010
A novel c.592-4_c.592-3delTT mutation in DGUOK gene causes exon skipping. 61 54
19900589 2010
Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. 61 54
20335584 2010
The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. 61 54
20093562 2010
HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. 54 61
19931264 2010
Natural anticoagulants can be useful predictors of severity in chronic liver disease. 54 61
20019598 2010
Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. 61 54
20150538 2010
Nonlinear distribution of adiponectin in patients with nonalcoholic fatty liver disease limits its use in linear regression analysis. 61 54
19770674 2010
Macrophage migration inhibitory factor expression and MIF gene -173 G/C polymorphism in nonalcoholic fatty liver disease. 54 61
19829123 2010
Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease. 54 61
19817962 2010
Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. 54 61
19839004 2010
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. 54 61
20176643 2010
[The roles of cyclooxygenase-2 and 5-lipoxygenase in liver disease]. 54 61
20196963 2010
Prevalence of genetic polymorphisms in the promoter region of the alpha-1 antitrypsin (SERPINA1) gene in chronic liver disease: a case control study. 61 54
20170533 2010
Animal models for hepatitis C and related liver disease. 54 61
20156300 2010
Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. 61 54
19793164 2010
Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. 61 54
19950230 2010
Nonalcoholic fatty liver disease in primary aldosteronism: a pilot study. 54 61
19910932 2010
Comparison of modes of prothrombin time reporting in patients with advanced liver disease associated with viral hepatitis. 54 61
19330428 2010
Plasma interleukin-18/interleukin-18 binding protein ratio in Chinese with NAFLD. 54 61
20422882 2010
Tumor necrosis factor-alpha accelerates apoptosis of steatotic hepatocytes from a murine model of non-alcoholic fatty liver disease. 54 61
20043871 2010
The role of cytokines in non-alcoholic fatty liver disease. 54 61
20460908 2010
The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. 54 61
19940802 2010
[Fatty liver disease, insulin resistance and adiponectin in an obese pediatric population]. 61 54
19850541 2009
Impact of fish oil-based lipid emulsion on serum triglyceride, bilirubin, and albumin levels in children with parenteral nutrition-associated liver disease. 54 61
19687773 2009
Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. 61 54
19769633 2009
Variants in the UGT1A1 gene and the risk of pediatric nonalcoholic fatty liver disease. 61 54
19948621 2009
Chronically inflamed livers up-regulate expression of inhibitory B7 family members. 54 61
19739236 2009
Serum retinol-binding protein 4 levels in patients with nonalcoholic fatty liver disease. 54 61
19525859 2009
Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. 61 54
19278843 2009
The unfolding clinical spectrum of POLG mutations. 61 54
19578034 2009
Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance. 54 61
19474742 2009
[Insulin resistance and islet beta cell function in type 2 diabetes mellitus and non alcoholic fatty liver disease.]. 61 54
20079327 2009
Xenobiotic-sensing nuclear receptors CAR and PXR as drug targets in cholestatic liver disease. 54 61
19925451 2009
Circulating and liver tissue levels of retinol-binding protein-4 in non-alcoholic fatty liver disease. 61 54
19624771 2009
Effect of extracorporeal liver support by molecular adsorbents recirculating system and Prometheus on redox state of albumin in acute-on-chronic liver failure. 54 61
19788461 2009

Variations for Liver Disease

ClinVar genetic disease variations for Liver Disease:

# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MYOM1 NM_003803.4(MYOM1):c.3260G>A (p.Trp1087Ter) SNV Likely pathogenic 804425 rs374670754 GRCh37: 18:3116372-3116372
GRCh38: 18:3116374-3116374
2 YARS1 NM_003680.3:c.611A>C SNV Uncertain significance 986742 GRCh37: 1:33256836-33256836
GRCh38: 1:32791235-32791235

Expression for Liver Disease

Search GEO for disease gene expression data for Liver Disease.

Pathways for Liver Disease

Pathways related to Liver Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
2 10.78 F2 ALB AFP

GO Terms for Liver Disease

Cellular components related to Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.97 SERPINA1 HGF GPT GGT1 F2 ALB
2 extracellular exosome GO:0070062 9.96 SERPINA1 PKHD1 PKD1 GPT GGT1 GANAB
3 endoplasmic reticulum GO:0005783 9.61 SERPINA1 SEC63 PRKCSH PKHD1 PKD1 HSD3B7
4 platelet alpha granule lumen GO:0031093 9.5 SERPINA1 HGF ALB
5 glucosidase II complex GO:0017177 9.16 PRKCSH GANAB
6 endoplasmic reticulum lumen GO:0005788 9.1 SERPINA1 PRKCSH GANAB F2 ALB AFP

Biological processes related to Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.55 SERPINA1 PRKCSH F2 ALB AFP
2 cellular response to insulin stimulus GO:0032869 9.5 PNPLA3 GPT ADIPOQ
3 response to sucrose GO:0009744 9.26 PNPLA3 ADIPOQ
4 liver development GO:0001889 9.26 SEC63 PRKCSH PKD1 HGF
5 nitrogen compound metabolic process GO:0006807 8.8 SEC63 PRKCSH PKD1

Sources for Liver Disease

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....